Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma

>The first patient dosing has been completed in a multi-center, randomized, controlled, and open-label phase 3 clinical study evaluating JS207 in combination with JS007 compared to toripalimab in combination with bevacizumab for the 1st-line treatment of advanced hepatocellular carcinoma.

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

>To date, the new drug application for JS001sc, in respect of all 13 approved indications of toripalimab (intravenous injection) (JS001), have been accepted.

Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

>Final analysis results from the NEOTORCH study were presented during ESMO 2026 and published in Annals of Oncology.

Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma

>First patient dosing has completed in the Phase 3 clinical trial of JS203 (CD20/CD3 bsAb) for the treatment of R/R DLBCL.